Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
Nirsevimab, a monoclonal antibody, is one of two new therapies that could dramatically reduce the risk of lung infections in infants.
New flu and COVID vaccines are available for everyone, and RSV vaccines for people 60 and older.
New study shows hospitalizations would fall by more than 50% and emergency department visits by over 30%.
According to the CDC, RSV is the leading cause of infant hospitalization in the U.S.
Adults ages 60 and older should discuss the new vaccines with their health care providers.
Arexvy RSV vaccine is now approved for individuals age 60 and older.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.